Profile data is unavailable for this security.
About the company
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
- Revenue in USD (TTM)310.23bn
- Net income in USD1.69bn
- Incorporated2001
- Employees42.00k
- LocationCencora Inc1 West First AvenueCONSHOHOCKEN 19428United StatesUSA
- Phone+1 (610) 727-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.cencora.com/
Mergers & acquisitions
| Acquired company | COR:NYQ since announced | Transaction value |
|---|---|---|
| Public Health Expertise LLC | 18.84% | -- |
| Retina Midco Inc | 26.16% | 5.10bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DexCom Inc | 4.15bn | 535.20m | 32.69bn | 10.30k | 63.93 | 14.42 | 42.99 | 7.88 | 1.30 | 1.30 | 10.11 | 5.78 | 0.6269 | 2.89 | 3.89 | 402,718.40 | 8.09 | 8.79 | 12.44 | 11.75 | 60.72 | 64.97 | 12.90 | 14.90 | 1.32 | -- | 0.5246 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| GE HealthCare Technologies Inc | 19.80bn | 2.18bn | 34.40bn | 53.00k | 15.80 | 3.74 | 12.20 | 1.74 | 4.76 | 4.76 | 43.13 | 20.07 | 0.6018 | 5.54 | 4.51 | 373,547.20 | 6.84 | -- | 9.67 | -- | 41.99 | 40.35 | 11.37 | 10.78 | 0.7601 | 8.18 | 0.483 | 1.19 | 0.6138 | 3.41 | 43.48 | 3.82 | 3.91 | -- |
| Agilent Technologies Inc | 6.63bn | 1.17bn | 35.02bn | 18.00k | 30.34 | 5.70 | 24.27 | 5.28 | 4.06 | 4.06 | 23.09 | 21.61 | 0.576 | 3.08 | 5.07 | 370,279.30 | 10.13 | 10.93 | 12.25 | 13.09 | 53.77 | 53.35 | 17.59 | 17.93 | 1.60 | 24.95 | 0.3629 | 21.83 | -4.73 | 4.75 | 3.95 | 3.77 | 19.36 | 7.80 |
| Resmed Inc | 5.02bn | 1.31bn | 37.30bn | 9.98k | 28.56 | 6.73 | 24.52 | 7.43 | 8.91 | 8.91 | 34.05 | 37.83 | 0.6983 | 2.45 | 5.65 | 503,159.20 | 18.26 | 14.24 | 20.73 | 16.53 | 58.76 | 56.85 | 26.15 | 20.35 | 2.49 | 58.86 | 0.1082 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.89 |
| IDEXX Laboratories Inc | 3.93bn | 894.97m | 42.89bn | 11.00k | 49.29 | 29.74 | 41.68 | 10.91 | 10.82 | 10.82 | 47.53 | 17.93 | 1.20 | 3.87 | 6.81 | 357,439.60 | 27.26 | 28.11 | 40.01 | 42.15 | 61.28 | 59.56 | 22.76 | 22.19 | 0.8111 | 53.37 | 0.3937 | 0.00 | 6.46 | 10.12 | 5.07 | 15.73 | -3.35 | -- |
| Veeva Systems Inc | 2.86bn | 780.66m | 45.08bn | 7.29k | 58.53 | 7.24 | 54.89 | 15.79 | 4.71 | 4.71 | 17.25 | 38.11 | 0.4093 | -- | 6.06 | 391,622.10 | 11.19 | 11.33 | 13.85 | 14.35 | 75.50 | 72.60 | 27.34 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Edwards Lifesciences Corp | 5.54bn | 1.44bn | 45.78bn | 15.80k | 32.20 | 4.52 | 29.01 | 8.27 | 2.42 | 7.00 | 9.31 | 17.28 | 0.4867 | 0.984 | 7.45 | 350,557.00 | 12.63 | 14.52 | 14.28 | 16.61 | 79.38 | 79.01 | 25.95 | 25.54 | 3.66 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Becton Dickinson and Co | 20.87bn | 1.50bn | 50.43bn | 74.00k | 34.08 | 2.00 | 13.04 | 2.42 | 5.16 | 5.16 | 71.96 | 88.07 | 0.3842 | 3.32 | 7.47 | 281,986.50 | 2.76 | 2.55 | 3.20 | 2.92 | 44.68 | 45.30 | 7.18 | 7.29 | 0.6427 | 7.18 | 0.4329 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Cencora Inc | 310.23bn | 1.69bn | 57.22bn | 42.00k | 34.26 | 56.48 | 20.35 | 0.1844 | 8.62 | 8.62 | 1,574.00 | 5.23 | 4.59 | 16.40 | 12.70 | 7,386,481.00 | 2.53 | 1.12 | 10.78 | 4.84 | 3.29 | 3.24 | 0.55 | 0.2556 | 0.517 | 17.30 | 0.8694 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 20.54m | 10.59% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 11.01m | 5.68% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 9.33m | 4.81% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 8.41m | 4.34% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2025 | 5.41m | 2.79% |
| Geode Capital Management LLCas of 31 Mar 2025 | 4.50m | 2.32% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 4.46m | 2.30% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 2.91m | 1.50% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 2.87m | 1.48% |
| Managed Account Advisors LLCas of 31 Mar 2025 | 2.65m | 1.37% |
